Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of MBL in preparing drug for preventing or treating disease induced by effector T cell

A technology for treating effects and diseases, applied in metabolic diseases, skin diseases, bone diseases, etc., to achieve the effect of strong regeneration ability and rich sources

Active Publication Date: 2017-08-18
XINXIANG MEDICAL UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, whether there are still unknown factors that promote the inhibitory effect of Treg cells needs to be further developed and studied urgently

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of MBL in preparing drug for preventing or treating disease induced by effector T cell
  • Application of MBL in preparing drug for preventing or treating disease induced by effector T cell
  • Application of MBL in preparing drug for preventing or treating disease induced by effector T cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Experimental Materials

[0032] 1. Source of cells used in the experiment

[0033] Newborn umbilical cord blood was collected from the third affiliated hospital of Xinxiang Medical College and the full-term healthy newborns of the Department of Obstetrics and Gynecology of Xinxiang First People's Hospital. The blood was collected from the placenta umbilical vein immediately after delivery and put into a blood collection bag containing 28 mL of preservation solution. All blood samples were delivered to the laboratory within 4 hours after sampling.

[0034] 2. Main reagents

[0035] The medium RPMI1640, Fetal bovine serum (FBS), and 10×PBS solution were all purchased from ThermoFisher Scientific.

[0036] Lymphocyte separation solution (Ficoll-Paque PLUS) is a sterile endotoxin test solution (<0.12EU / mL) of FicollTM PM400 and sodium diatrizoate with a density of 1.077 g / mL, purchased from GE Healthcare Life Sciences.

[0037] Anti-human CD3 monoclonal antibody (CD3mAb), anti-human ...

Embodiment 2

[0094] Experimental Materials

[0095] 1. Source of cells used in the experiment

[0096] Reference example 1

[0097] 2. Main reagents

[0098] Reference example 1

[0099] 3. Main instruments and equipment

[0100] Reference example 1

[0101] 4. Preparation of common reagents

[0102] Reference example 1

[0103] experimental method

[0104] 1. Preparation of cord blood mononuclear cells

[0105] Reference example 1

[0106] 2. Coated with anti-CD3mAb

[0107] Reference example 1

[0108] 3. Magnetic sorting of CD4+CD25-T cells and CD4+CD25+T cells

[0109] Sample preparation

[0110] Density gradient centrifugation was used to separate peripheral mononuclear cells. In order to remove platelets, the cells were resuspended in a buffer and centrifuged at 200×g for 10-15 minutes. The supernatant was carefully aspirated and washed repeatedly.

[0111] Magnetic labeling of non-CD4+ T cells

[0112] The entire process should be completed quickly and the cells should be kept in a pre-cooled state to pre...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of MBL in preparing a drug for preventing or treating disease induced by an effector T cell and belongs to the technical field of a novel application of mannan binding lectin. The key point of the technical scheme is as follows: the invention relates to the application of MBL in preparing a drug for preventing or treating infectious diseases, autoimmune diseases or / and allergic diseases induced by the effector T cell, wherein MBL realizes functions of the drug by enhancing iTreg cell and inhibiting proliferation of the effector T cell. Through researches, a novel factor of adjusting the inhibition function of the Tregs cell is obtained, that is, MBL directly enhances the inhibition action of the Tregs cell on proliferation of the effector T cell. The application disclosed by the invention highlights a novel function of MBL, and MBL not only plays an important anti-infection role in inherent immunity, but also can be a pertinent target spot for treating various autoimmune diseases and inflammatory diseases in intervention of the function of the Tregs cell.

Description

Technical field [0001] The invention relates to the technical field of new uses of mannan-binding lectins, in particular to the application of MBL in the preparation of drugs for preventing or treating effector T cell-induced diseases. Background technique [0002] Mannan-binding lectin (mannan-binding lectin, MBL) is a highly conserved plasma protein mainly secreted by hepatocytes, and is a member of the collectins family in the C-type lectin superfamily. MBL is also an acute phase reactive protein, and its plasma concentration can increase by 2-3 times during stress (such as pathogen infection, surgery, etc.). MBL, known as the ante-antibody, uses its carbohydrate recongnition domain (CRD) to broadly recognize sugar structures on the surface of a variety of pathogens such as bacteria, viruses, parasites, and fungi, including D-mannose. Sugar, L-fucose, N-acetylglucosamine, N-acetylmannosamine, etc. Its collagen-like region (CLR) binds to MBL-associated serine protease (MBL-MA...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/36A61P33/02A61P33/06A61P31/04A61P31/22A61P31/18A61P1/16A61P31/20A61P31/14A61P37/02A61P3/10A61P29/00A61P19/02A61P17/00A61P5/16A61P17/14A61P37/08A61P11/02A61P11/06
CPCA61K38/36Y02A50/30
Inventor 王凡平王明永穆永慧张卫斌王帅杨帆吴敏娜陈晨段巨洪牛志国
Owner XINXIANG MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com